Company: Inhibrx, Inc.
Form Type: 8-K
Filing Date: 2024-08-13
Corporate Action: Spin-off
Type: Update
Accession Number: 000200791924000031
Comments: The announcement pertains to financial results and updated corporate presentations by Inhibrx Biosciences, Inc., and does not indicate a spin-off.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-42031
Access 12: 000200791924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: S-1
Filing Date: 2024-06-11
Corporate Action: Spin-off
Type: Update
Accession Number: 000200791924000011
Comments: The announcement does not indicate any spin-off; rather, it appears to be related to general corporate updates and financial reporting.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: Not Found
Access 12: 000200791924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-30
Corporate Action: Spin-off
Type: Update
Accession Number: 000110465924066645
Comments: Inhibrx, Inc. has successfully executed a spin-off, distributing 92% of the shares of its subsidiary, Inhibrx Biosciences, Inc., to its existing shareholders. The transaction was completed on May 29, 2024, with shareholders receiving one share of the spin-off company for every four shares they held in the parent company as of the record date of May 17, 2024. This strategic move allows the newly formed entity to operate independently, creating clear market opportunities for both Inhibrx and its subsidiary.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-42031
Access 12: 000110465924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-30
Corporate Action: Spin-off
Type: Update
Accession Number: 000110465924066650
Comments: The document announces the completion of a spin-off transaction where Inhibrx, Inc. distributed 92% of the common stock of its subsidiary, Inhibrx Biosciences, Inc. (referred to as SpinCo) to its stockholders. The distribution took place on a pro rata basis, with stockholders receiving one share of SpinCo for every four shares of Inhibrx common stock. SpinCo will operate as a separate public company and Inhibrx retained 8% of SpinCo's shares.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
Access 12: 000110465924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-24
Corporate Action: Spin-off
Type: Update
Accession Number: 000110465924065125
Comments: Inhibrx, Inc. has announced the approval of a spin-off to create a new entity, SpinCo, which will hold assets and liabilities not related to the 101 Business. The spin-off is set to take place on May 29, 2024, with shareholders receiving shares of SpinCo based on their holdings in Inhibrx. The registration statement for SpinCo was declared effective by the SEC on the same date, and the move is part of a broader merger with Aventis Inc. The transaction is well-supported by the company's shareholders, indicating strong backing for the company's strategic realignment.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
Access 12: 000110465924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-24
Corporate Action: Spin-off
Type: New
Accession Number: 000110465924065140
Comments: The document discusses the distribution of 92% of Inhibrx Biosciences, Inc.'s common stock to the shareholders of Inhibrx, Inc. The distribution is expected to be effective as of May 29, 2024.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-42031
:
Percentage Spun Off: 92
Effective Date: 2024-05-29
Form Type: 8-K
Filing Date: 2024-05-17
Corporate Action: Spin-off
Type: Update
Accession Number: 000110465924063107
Comments: Inhibrx, Inc. is set to distribute 92% of the shares of its subsidiary, Inhibrx Biosciences, Inc. (referred to as SpinCo), to its common stockholders in a significant spin-off. This follows a merger agreement with Aventis Inc. where the company will become a wholly owned subsidiary of Aventis. Additionally, a special shareholder meeting to vote on the merger and distribution is scheduled for May 24, 2024. This is a valid spin-off transaction as opposed to a simple merger or acquisition.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
Access 12: 000110465924
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-09
Corporate Action: Spin-off
Type: Update
Accession Number: 000173961424000031
Comments: The announcement pertains to Inhibrx, Inc.'s financial results for the quarter ending March 31, 2024, and does not involve a spin-off. The material included in the report is intended purely for informational purposes regarding the company's operational and financial performance, rather than a new entity formation or division.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
Access 12: 000173961424
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-05-08
Corporate Action: Spin-off
Type: Update
Accession Number: 000095014224001307
Comments: Inhibrx, Inc. announced a spin-off of 92% of the shares of its subsidiary, Inhibrx Biosciences, Inc., scheduled for distribution to holders of the Company’s common stock. The record date for the spin-off is noted as May 17, 2024, with the distribution planned for May 29, 2024. The announcement also highlights the concurrent expectation of a merger with Sanofi to take place the following day, on May 30, 2024. All activities are contingent on closing conditions and shareholder approval scheduled for May 24, 2024.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
Access 12: 000095014224
: 0
Percentage Spun Off: 92
Effective Date: 2024-05-29
Spin Off Id: 385
Form Type: 8-K
Filing Date: 2024-03-12
Corporate Action: Spin-off
Type: New
Accession Number: 000110465924033457
Comments: Inhibrx, Inc. announced a proposed acquisition by Aventis Inc. and mentioned the spin-off of certain assets and liabilities, including those related to specific therapeutic candidates. The document discusses the regulatory requirements and approvals needed to finalize the transaction, highlighting that one condition was met with the expiration of a regulatory waiting period. It does not provide specific details regarding the percentage of assets being spun off or further identification details for the new entity.
Document Link: View Document
Additional details:
Newco Cik: 2007919
Parent Cik: 1739614
File Number: 001-39452
:
Percentage Spun Off: 92
Effective Date: 2024-05-29